Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marlena Walls

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Cancer Drug Targets|January 10, 2013
Targeting the mTOR pathway in tumor malignancyHengmiao Cheng, Marlena Walls, Sangita M Baxi, et al.
Cancer Letters|October 8, 2010
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cellsPramod P Mehta, Pei-Pei Kung, Shinji Yamazaki, et al.
Molecular Cancer Therapeutics|June 10, 2010
Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial designPing Wei, Marlena Walls, Ming Qiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2013
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216Marlena Walls, Sangita M Baxi, Pramod P Mehta, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2009
Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitorsAmogh Boloor, Denise Hanway, Maria Joshi, et al.
Molecular Cancer Therapeutics|February 8, 2017
Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma GrowthXinqiang Huang, Jill Magnus, Vivek Kaimal, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor ActivityKevin K-C Liu, JinJiang Zhu, Graham L Smith, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug DesignHengmiao Cheng, Chunze Li, Simon Bailey, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Cancer Drug Targets|January 10, 2013
Targeting the mTOR pathway in tumor malignancyHengmiao Cheng, Marlena Walls, Sangita M Baxi, et al.
Cancer Letters|October 8, 2010
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cellsPramod P Mehta, Pei-Pei Kung, Shinji Yamazaki, et al.
Molecular Cancer Therapeutics|June 10, 2010
Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial designPing Wei, Marlena Walls, Ming Qiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2013
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216Marlena Walls, Sangita M Baxi, Pramod P Mehta, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2009
Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitorsAmogh Boloor, Denise Hanway, Maria Joshi, et al.
Molecular Cancer Therapeutics|February 8, 2017
Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma GrowthXinqiang Huang, Jill Magnus, Vivek Kaimal, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor ActivityKevin K-C Liu, JinJiang Zhu, Graham L Smith, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug DesignHengmiao Cheng, Chunze Li, Simon Bailey, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 1